PepTrackevidence-graded reference
Sermorelin
fig.1 — stylized molecular motif
GH secretagogue

Sermorelin

GHRH(1-29) · GRF 1-29 · Geref

Cheapest, most accessible GH-optimization entry (telehealth under ~$130/mo); heavily marketed; the most legally secure compounded peptide.

Evidence
Bhuman trials
Status
Research-use-only — gray marketas of 2026-06
Approval
Not approved
Category
GH secretagogue
Route
Subcutaneous
Demand rank
#10 most-searched
01Dosing & Protocol
Typical · reference only
~200-300 mcg SC nightly (overlaps old adult dose); clinics 100-500 mcg/night, cycled
Titration
Start 100-200 mcg, reassess IGF-1 at 8-12 wks
Reconstitution — illustrative, not a recommendation
15 mg vial + 7.5 mL BAC = 2 mg/mL; 200 mcg = 10 U, 300 mcg = 15 U on U-100 (1 U = 20 mcg). NOTE: RxList prints '0.2-0.3 mcg' (typo for mg) - mcg/mg confusion = 1000x.
Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial.
02Regulatory Status
Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Most legally secure compounded peptide, but wellness use is OFF-LABEL and not FDA-approved for anti-aging.
Status
Research-use-only — gray market
503A bulks
Listed
Category 2
Distinct path - former approved drug (Geref, off-market 2008); 503A/503B compoundable
PCAC review
none scheduled
WADA
Prohibited
03Evidence — the honest read
What the evidence actually shows

Old, small human trials (1992-1999); none in healthy adults for anti-aging. Flagship 'Khorram 1997' result actually used a different analog ([Nle27]GHRH).

04Safety
Contraindications
  • Active malignancy
  • Pituitary/intracranial structural disease
  • Pregnancyhard stop
  • Untreated hypothyroidism
  • Uncontrolled diabetes / proliferative retinopathy
Key interactions
  • Glucocorticoids, somatostatin analogs, untreated hypothyroidism (blunt GH response)
  • Antidiabetics (GH lowers insulin sensitivity)
Serious signals
  • Outlier 'up to 2 mg/day' figure (~7-10x dose) has no safety basis - cap by IGF-1
Monitoring
IGF-1 within age/sex range; glucose/HbA1c.
05Related in GH secretagogue
CJC-1295 / Ipamorelin
human trials
grade B →
Tesamorelin
FDA-approved RCTs
grade A →
06Sources
1Empower/Defy pharmacy guidance
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: med-high
← All peptides
GH secretagogue

Sermorelin

GHRH(1-29) · GRF 1-29 · Geref

Cheapest, most accessible GH-optimization entry (telehealth under ~$130/mo); heavily marketed; the most legally secure compounded peptide.

Evidence
B
human trials
Status
Research-use-only — gray market
as of 2026-06
FDA approval
Not approved
off-label / gray
Route
Subcutaneous
Clinic protocol
Demand
#10
most-searched
WADA
Prohibited
tested athletes — avoid
01

Dosing & protocol

Clinic protocol. Clinic-protocol / off-label extrapolation — not an FDA-approved regimen.
Typical — reference only

~200-300 mcg SC nightly (overlaps old adult dose); clinics 100-500 mcg/night, cycled

Worked reconstitution example

15 mg vial + 7.5 mL BAC = 2 mg/mL; 200 mcg = 10 U, 300 mcg = 15 U on U-100 (1 U = 20 mcg). NOTE: RxList prints '0.2-0.3 mcg' (typo for mg) - mcg/mg confusion = 1000x.

Titration

Start 100-200 mcg, reassess IGF-1 at 8-12 wks

Units are not milligrams. mg-vs-mcg confusion drives documented 5–1000× overdoses — always recompute for your own vial (use the calculator →).
02

Regulatory status

Removal from Category 2 ≠ legal to compound ≠ FDA-approved. Most legally secure compounded peptide, but wellness use is OFF-LABEL and not FDA-approved for anti-aging.
StatusResearch-use-only — gray market
503A bulksListed
Category 2 (2026)Distinct path - former approved drug (Geref, off-market 2008); 503A/503B compoundable
PCAC reviewnone scheduled
WADAProhibited (S0)
03

Evidence — the honest read

Bhuman trials

Old, small human trials (1992-1999); none in healthy adults for anti-aging. Flagship 'Khorram 1997' result actually used a different analog ([Nle27]GHRH).

04

Safety

Contraindications
  • Active malignancy
  • Pituitary/intracranial structural disease
  • Pregnancyhard stop
  • Untreated hypothyroidism
  • Uncontrolled diabetes / proliferative retinopathy
Key interactions
  • Glucocorticoids, somatostatin analogs, untreated hypothyroidism (blunt GH response)
  • Antidiabetics (GH lowers insulin sensitivity)
Serious signals
  • Outlier 'up to 2 mg/day' figure (~7-10x dose) has no safety basis - cap by IGF-1
Monitoring

IGF-1 within age/sex range; glucose/HbA1c.

06

Sources

01Empower/Defy pharmacy guidance
＋PepTrack research dossier — iterations 1–4, 584 de-duplicated sources, adversarially verified.
Not medical or legal advice. Educational / harm-reduction reference. Regulatory and dosing claims in this field move monthly — re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.
Last reviewed — 2026-06-13 · confidence: med-high